Previous 10 | Next 10 |
– QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company de...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera Pharmaceuticals (NASDAQ: DCPH ) stock absolutely imploded in November. Shares lost more than two-thirds of their value virtually overnight. Source: Iryna Imago / Shutterstock.com DCPH stock plunged aft...
On a bad day for the stock market overall, Deciphera Pharmaceuticals (NASDAQ: DCPH) was quite the happy standout. Shares of the biotech closed more than 12% higher on Tuesday thanks to the launch of a new company initiative. Deciphera is in restructuring mode, with the aim being...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deciphera Pharmaceuticals (NASDAQ: DCPH ) is a biotech company that develops drugs mainly for the treatment of cancer. Right now, DCPH stock shares are down nearly 85% year-to-date (YTD), at $7.70 as of the close...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sometimes, a big sell off can also be a big opportunity. But that’s not the case here with biotech play Deciphera Pharmaceuticals (NASDAQ: DCPH ). On Nov. 5, DCPH stock took a sudden plunge of more ...
Deciphera Pharmaceuticals (DCPH +7.9%) is undertaking a corporate restructuring and reducing its workforce by ~35%, to prioritize clinical development of select programs, streamline commercial operations and extend its cash runway. The company will focus its resources on the continued ad...
Deciphera Pharmaceuticals (NASDAQ:DCPH) will undergo a corporate restructuring that will result in the elimination of 35% of its workforce and the ending a phase 1/2 program for solid tumors. The company said it will focus resources on two candidates, vemseltinib and DCC-3116. The former is i...
– Resources Focused on the Clinical Development of Vimseltinib and DCC-3116; Rebastinib Program Discontinued – – US Commercial Operations Streamlined and Launches Planned in Select European Markets for QINLOCK ® – – Workf...
Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagship drug will not be moving from later-line to second-line therapy for GIST. With b...
Shares of Deciphera Pharmaceuticals are (NASDAQ:DCPH) up 6% after the European Commission approved Qinlock (ripretinib) as a fourth-line treatment for gastrointestinal stromal tumors. A pivotal trial showed that the drug increased overall survival compared to best supportive care. It also mai...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...